Starling Oncology, Inc. STLN
$6.94
$0.314.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 44.92% | 32.39% | 6.27% | 5.63% | 7.90% |
| Total Depreciation and Amortization | -0.87% | 2.95% | 10.45% | 14.00% | 9.34% |
| Total Amortization of Deferred Charges | -47.26% | -50.97% | 32.91% | 39.57% | 46.66% |
| Total Other Non-Cash Items | -47.09% | 28.95% | 159.17% | 79.29% | -2.77% |
| Change in Net Operating Assets | -30.50% | -103.66% | -92.66% | -45.58% | 3,093.90% |
| Cash from Operations | 103.22% | -39.45% | 7.35% | 31.73% | 76.72% |
| Capital Expenditure | -25.10% | -11.61% | 15.54% | -34.54% | 31.65% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | -83.68% |
| Cash from Investing | -149.94% | -114.70% | -106.65% | -106.32% | -87.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 94.53% | 94.80% | -1,659.67% | -1,506.38% | -1,091.63% |
| Issuance of Common Stock | -13.74% | 12.14% | 43,413.33% | 15,081.91% | 8,705.47% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 78.45% | 97.89% | 97.89% | 100.00% | 94.15% |
| Cash from Financing | 542.46% | 323.05% | 430.96% | 249.91% | 43.37% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 276.16% | -356.76% | -199.52% | -199.38% | -181.41% |